Press-center
2023
Monrol Announces Investment to Expand its n.c.a. Lu-177 Production Capacity
ISTANBUL--(BUSINESS WIRE)--Eczacıbaşı Monrol Nuclear Products Co. (Monrol), one of the world's leading radiopharmaceutical producers, has decided to invest 35 million Euros to increase its production capacity for non-carrier-added Lutetium-177 (n.c.a. Lu-177) in response to growing global demand for this product.
2022
Monrol and FutureChem Announced a Clinical Supply Partnership
ISTANBUL & SEOUL--(BUSINESS WIRE)--Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) is delighted to announce that it has reached an agreement in principal with FutureChem based in Seoul, South Korea, a radiopharmaceutical company, for the clinical supply..
2022
Monrol Will Establish a Legal Entity and Manufacturing Facility in Germany
ISTANBUL--(BUSINESS WIRE)--Following an ongoing assessment of its entire operation, Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has decided to establish a legal entity and manufacturing facility in Germany.
2022
Monrol and ImaginAb Announce Supply, Manufacturing and Distribution Partnership
Inglewood, California and Istanbul, Turkey – June 9, 2022 - ImaginAb, Inc., a market leading global biotechnology company focused on developing next generation immuno-oncology imaging agents and radioligand therapy (RLT), is delighted to announce that...
2022
Monrol Is Partnering With Telix Pharmaceuticals, Supplying Lutetium nca Lu 177 for the Manufacturing of Clinical Doses for the Phase II STARLITE 2 Study At MSK and Manufacturing Clinical Doses for Telix’s Phase III ZIRCON Trial
ISTANBUL--(BUSINESS WIRE)--Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has today announced that the first patient has been dosed in the ‘STARLITE 2’ Phase II study of Telix Pharmaceuticals Limited (Telix) investigational renal cancer therapy product..
2022
Monrol Signing Agreement to License its GMP Grade Lu-177 n.c.a Production Technology to Curium
ISTANBUL--(BUSINESS WIRE)--Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has today announced it has signed an agreement with Curium Netherlands B.V (Curium) to license its GMP grade medical radioisotope, no-carrier-added177Lu (n.c.a.177Lu)...
2021
MTTI and Monrol Have Signed a Clinical Supply Agreement for Lu-177 n.c.a.
WEST CHESTER, Pa. & ISTANBUL--(BUSINESS WIRE)--Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) today announced their agreement with Molecular Targeting Technologies, Inc. (MTTI), a clinical stage biotech company focused on developing innovative...
2020
First Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product in Turkey
MELBOURNE, Australia and ISTANBUL, Turkey, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) and Eczacıbaşı-Monrol Nuclear Products Co. (‘Eczacıbaşı Monrol’) are pleased to announce that the first...
2019
Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement
MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products...